The drug, AZD-103/ELND005, is currently being evaluated in multiple phase I clinical studies, and the companies anticipate starting phase II clinical studies around the end of 2007.
Fast track designation is intended to facilitate the development and expedite the review of a drug or biologic if it is intended for the treatment of a serious or life-threatening condition, and it demonstrates the potential to address unmet medical needs for such a condition.